Vaccinating cattle for E. coli O157:H7 has, in theory, long been a favorite pre-harvest intervention strategy for consumers, and now Kansas State University has found it appears to work. K State has found a commercial vaccine for cattle can effectively reduce levels of E. coli by more than 50 percent by using two doses rather than the manufacturer’s recommended three doses. The fact that it can be effect at a lower dose means it will cost the beef industry less to put it to work. While K State did not say so in their press release, it appears as though the target of their research most certainly is the “E coli Bacterial Extract Vaccine with SRP® Technology.” Madison, NJ-based Pfizer Animal Health acquired worldwide rights to the product, which was developed and is manufactured by Wilmar, MN-based Epitopix LLC. The vaccine first created a buzz in 2010 when giant Cargill Meat Solutions tested it on 85,000 head of cattle in Fort Morgan CO. It was only a couple months later than Pfizer bought the vaccine. Ever since, the cattle industry has been waiting for the independent research that K State has provided. Pfizer says their Extract Vaccine is the “first and only” USDA approved vaccine for reducing E. coli pathogens in the intestines of cattle and from shedding into the environment. David Renter, associate professor of epidemiology, is the principal investigator on a project that researched the effectiveness of products used to prevent the shedding of E. coli O157:H7 in cattle. The research appears in a recent online version of the journal Vaccine and helps improve current preventative methods for addressing food safety concerns. While E. coli O157:H7 does not affect cattle, it causes a potentially deadly foodborne disease in humans. In the last 20 years, the beef industry has used numerous pre- and post-harvest (slaughter) interventions to reduce the presence of E. coli. Some are more successful than others. “We wanted to test how well these products work to control E. coli O157:H7 in a commercial feedlot with a large population of cattle that were fed in the summer and may be expected to have a high level of E. coli O157:H7,” Renter said. Other involved K State researchers include T.G. Nagaraja, university distinguished professor of microbiology; Nora Bello, assistant professor of statistics; Charley Cull, doctoral student in pathobiology, and Zachary Paddock, doctoral student in pathobiology. Abram Babcock, an August 2010 Kansas State University doctoral graduate, was also involved in the research. Using a commercial feedlot setting, the researchers studied more than 17,000 cattle during an 85-day period. They studied two products: a vaccine and a low-dose direct-fed microbial. “What’s unique about this study is the number of animals we used, the research setting and that we used commercial products in the way that any cattle producer could use them,” Renter said. “We didn’t want it to be any different than the way somebody would use the products in a commercial feedlot.” The researchers found that the vaccine reduced the number of cattle that were shedding E. coli O157:H7 in feces by more than 50 percent. E. coli shedding was reduced by more than 75 percent among cattle that were high shedders of E. coli. While the vaccine label suggests that it is given in three doses, the researchers found that two doses of the vaccine significantly reduced E. coli. “Showing that level of efficacy with two doses is really important because a shift to two doses from three could significantly cut costs for the beef industry,” Renter said. “In terms of logistics, it can be difficult for commercial feedlot production systems to vaccinate animals three times. Both of these benefits help when considering how the vaccine can be adopted and implemented in the industry.” The researchers also discovered that the low-dose direct-fed microbial product did not work as well as the vaccine. Renter said while the study used a lower dose of the direct-fed microbial and could find no evidence that it reduced E. coli shredding, it is possible that the direct-fed microbial product is more effective at a higher dose. “This vaccine is an option for reducing E. coli,” Renter said. “We have shown that this vaccine works and that it is a tool that could be adopted in the industry.” A $1 million USDA grant helped support the three-year project.